These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7973366)

  • 1. Issues with biotechnology products in toxicologic pathology.
    Terrell TG; Green JD
    Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals.
    Pilling AM
    Toxicol Pathol; 1999; 27(6):678-88. PubMed ID: 10588549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Special considerations concerning regulatory requirements and drug development for peptides and biotech products in the EU.
    Braun A; Gassmann R; Kraus K; Lorenzi G; Weigel U
    Pharm Acta Helv; 1996 Dec; 71(6):447-58. PubMed ID: 8997177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety evaluation of biological and biotechnology-derived medicines.
    Dayan AD
    Toxicology; 1995 Dec; 105(1):59-68. PubMed ID: 8638284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety evaluation of biotechnology products.
    Zbinden G
    Drug Saf; 1990; 5 Suppl 1():58-64. PubMed ID: 2182064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.
    Ponce R; Abad L; Amaravadi L; Gelzleichter T; Gore E; Green J; Gupta S; Herzyk D; Hurst C; Ivens IA; Kawabata T; Maier C; Mounho B; Rup B; Shankar G; Smith H; Thomas P; Wierda D
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):164-82. PubMed ID: 19345250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Preclinical evaluation of the safety of biotechnology products: specific aspects].
    Descotes J; Ravel G; Vial T
    Therapie; 2003; 58(2):139-43. PubMed ID: 12942854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.
    Brennan FR; Shaw L; Wing MG; Robinson C
    Mol Biotechnol; 2004 May; 27(1):59-74. PubMed ID: 15122047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxicity testing of biotechnology-derived products. Report of a GUM task force. Gesellschaft für Umweltmutationsforschung.
    Gocke E; Albertini S; Brendler-Schwaab S; Müller L; Suter W; Würgler FE
    Mutat Res; 1999 Mar; 436(2):137-56. PubMed ID: 10095137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of biotechnology products for therapeutic use.
    Sims J
    Toxicol Lett; 2001 Mar; 120(1-3):59-66. PubMed ID: 11323162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best practices for veterinary toxicologic clinical pathology, with emphasis on the pharmaceutical and biotechnology industries.
    Tomlinson L; Boone LI; Ramaiah L; Penraat KA; von Beust BR; Ameri M; Poitout-Belissent FM; Weingand K; Workman HC; Aulbach AD; Meyer DJ; Brown DE; MacNeill AL; Bolliger AP; Bounous DI
    Vet Clin Pathol; 2013 Sep; 42(3):252-69. PubMed ID: 23889060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory forum opinion piece*: supporting the need for international harmonization of safety assessments for food flavoring substances.
    Konishi Y; Hayashi SM; Fukushima S
    Toxicol Pathol; 2014 Aug; 42(6):949-53. PubMed ID: 23881932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative strategies for toxicity testing of species-specific biopharmaceuticals.
    Bussiere JL; Martin P; Horner M; Couch J; Flaherty M; Andrews L; Beyer J; Horvath C
    Int J Toxicol; 2009; 28(3):230-53. PubMed ID: 19546261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conclusions of the satellite symposium of the Eurotox '91 Congress on Safety Aspects of Biotechnology-Derived Drugs.
    Hum Exp Toxicol; 1992 Sep; 11(5):369-72. PubMed ID: 1358153
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilars--global issues, national solutions.
    Knezevic I; Griffiths E
    Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical safety evaluation of human gene therapy products.
    Verdier F; Descotes J
    Toxicol Sci; 1999 Jan; 47(1):9-15. PubMed ID: 10048148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.